Edesa Biotech Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment

Edesa Biotech (EDSA) has reaffirmed its plan to begin enrollment for a Phase 2 clinical trial of its vitiligo treatment EB06 in mid-2026. The trial will assess the safety and efficacy of EB06, a monoclonal antibody targeting CXCL10, and is expected to start in Canada after regulatory approval. The company has selected JSS Medical Research as its clinical research organization.

By Maham Fatima Mon, April 20, 2026 at 5:14 PM GMT+3 2 min read · Yahoo Finance · April 20, 2026, 14:14 UTC

Topics: clinical trials drug development EB06 Phase 2 study vitiligo treatment

Read the full article at Yahoo Finance

More World news

Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC
NYSE Gains $500 Billion in Market Capitalization via Nine Major Listing Transfers PR Newswire · November 12, 2026, 18:05 UTC
PenFed Foundation Grants $25,000 to Northern Virginia Vietnam Veterans Foundation PR Newswire · November 12, 2026, 18:06 UTC
Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC